Insider Trading April 10, 2026 09:10 PM

Aehr Test Systems Director Sells $205K in Stock as Shares Trade Near Yearly Peak

Director Laura Oliphant disposes of 3,000 shares; company posts mixed Q3 fiscal 2026 results with strong bookings but a revenue miss

By Leila Farooq AEHR
Aehr Test Systems Director Sells $205K in Stock as Shares Trade Near Yearly Peak
AEHR

Laura Oliphant, a director at Aehr Test Systems (NASDAQ: AEHR), sold 3,000 shares on April 9, 2026, for $68.3575 each, generating proceeds of $205,072. The transaction occurred while the share price sits close to its 52-week high of $72.50 after a 727% gain over the past year. Following the sale Oliphant maintains direct and indirect holdings totaling 23,097 shares when including restricted stock units and trust-held shares. The company reported mixed third-quarter fiscal 2026 results, beating EPS expectations but missing on revenue, while recording strong bookings and prompting an upgraded price target from Lake Street.

Key Points

  • Director Laura Oliphant sold 3,000 Aehr Test Systems shares on April 9, 2026, for $68.3575 each, totaling $205,072.
  • Oliphant retains direct ownership of 18,432 shares (including unvested restricted stock units) and indirect ownership of 4,665 shares held by a trust.
  • Aehr Test Systems reported Q3 fiscal 2026 EPS of -$0.05 (better than -$0.07 expected), revenue of $10.3 million (below $10.8 million forecast), and strong bookings of $37.2 million with a book-to-bill ratio above 3.5x; Lake Street raised its price target to $56 and kept a Buy rating.

Laura Oliphant, who serves on the board of Aehr Test Systems (NASDAQ: AEHR), completed the sale of 3,000 shares of common stock on April 9, 2026, at a per-share price of $68.3575. The transaction produced gross proceeds of $205,072. The disposal was disclosed in a Form 4 filing with the Securities and Exchange Commission.

The sale took place as Aehr Test Systems shares are trading near their 52-week high of $72.50, following an extraordinary 727% return over the previous 12 months. After the disposition, Oliphant still directly holds 18,432 shares - a figure that the company notes includes shares subject to unvested restricted stock units - and she indirectly holds an additional 4,665 shares that are held by a trust, for a combined direct and indirect position disclosed in the filing.

On the valuation front, InvestingPro’s Fair Value analysis flags AEHR as appearing overvalued relative to its model, ranking it among the stocks deemed most overvalued under that assessment. The InvestingPro service also lists 19 additional tips for investors seeking deeper information on AEHR’s performance and valuation, according to the original report.

Financial results for the third quarter of fiscal 2026 were mixed. Aehr Test Systems reported an earnings per share (EPS) of negative $0.05, which was better than the consensus expectation of negative $0.07. Revenue for the quarter was $10.3 million, below the anticipated $10.8 million. Despite that revenue shortfall, the company recorded quarterly bookings of $37.2 million, producing a book-to-bill ratio in excess of 3.5x, a metric cited as evidence of strong demand during the period.

Market reaction among some analysts reflected the company’s bookings strength. Lake Street responded by raising its price target on Aehr Test Systems from $50 to $56 while keeping a Buy rating in place, specifically pointing to bookings momentum in its rationale.

The facts disclosed in regulatory filings and the company’s reported results provide visibility into both insider activity and operational performance in the most recent quarter. The ownership changes disclosed in the Form 4, the valuation assessment reported by InvestingPro, and the company’s earnings, revenue, and bookings metrics together form the factual basis for assessing the company’s current position in the market.


Note: This article focuses on the reported insider transaction, the company’s recent quarterly results, and related analyst and valuation commentary as presented in company filings and third-party commentary. It does not attempt to draw conclusions beyond the information disclosed in those sources.

Risks

  • Valuation concerns - InvestingPro’s Fair Value analysis indicates AEHR appears overvalued and places it among the most overvalued stocks noted by that service, which may affect investor perceptions.
  • Revenue shortfall - The company’s reported revenue of $10.3 million missed the $10.8 million expectation, introducing uncertainty around near-term top-line performance.
  • Insider sale timing - The director’s sale occurred while shares traded near a 52-week high, which may prompt investor attention to insider liquidity relative to ownership levels; the filing shows remaining direct and indirect holdings but the sale reduces her immediate stake.

More from Insider Trading

CoreWeave CSO Venturo Disposes $5.51 Million in Class A Shares Under 10b5-1 Plan Apr 10, 2026 CoreWeave COO Sells Shares as Company Signs Major AI and Cloud Deals, Prices Convertible Notes Apr 10, 2026 CoreWeave Executive Sells Nearly $900,000 in Class A Stock as Company Announces Major Contract and Financing Moves Apr 10, 2026 CoreWeave CEO Sells $5.57 Million in Class A Shares as Company Advances Major AI and Cloud Deals Apr 10, 2026 CoreWeave CFO Executes Small Sale as Company Secures Major Contract and Debt Financing Apr 10, 2026